Reported resultsCompany-reported
What was reported
MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 11, 2026 · Open the source ↗
What the evidence supports
Neuronetics published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $41.6 million | “• Total revenue of $41.6 million, up 9.1% compared to the second quarter of 2025” Mentions: revenue |
| $26.9 million | “• Greenbrook revenue of $26.9 million, up 16.8% compared to the second quarter of 2025” Mentions: revenue |
| $0.3 million | “• Adjusted EBITDA of $0.3 million compared to a loss of $5.6 million in the second quarter of 2025” Mentions: ebitda |
| $5.6 million | “• Adjusted EBITDA of $0.3 million compared to a loss of $5.6 million in the second quarter of 2025” Mentions: ebitda |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNeuronetics Reports Second Quarter 2026 Financial and Operating ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 11, 2026 · Open the source ↗
Press release lead paragraphMALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 11, 2026 · Open the source ↗
Amount stated in press release• Total revenue of $41.6 million, up 9.1% compared to the second quarter of 2025U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 11, 2026 · Open the source ↗
Amount stated in press release• Greenbrook revenue of $26.9 million, up 16.8% compared to the second quarter of 2025U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 11, 2026 · Open the source ↗
Amount stated in press release• Adjusted EBITDA of $0.3 million compared to a loss of $5.6 million in the second quarter of 2025U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 11, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.